Krystal Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KRYS and other ETFs, options, and stocks.

About KRYS

Krystal Biotech, Inc. operates as a biotechnology company, which engages in discovery, development, manufacturing, and commercialization of pharmaceutical products. It offers the product, VYJUVEK. 

CEO
Krish S. Krishnan
CEOKrish S. Krishnan
Employees
295
Employees295
Headquarters
Pittsburgh, Pennsylvania
HeadquartersPittsburgh, Pennsylvania
Founded
2016
Founded2016
Employees
295
Employees295

KRYS Key Statistics

Market cap
9.37B
Market cap9.37B
Price-Earnings ratio
41.44
Price-Earnings ratio41.44
Dividend yield
—
Dividend yield—
Average volume
275.29K
Average volume275.29K
High today
$331.03
High today$331.03
Low today
$315.39
Low today$315.39
Open price
$329.94
Open price$329.94
Volume
225.28K
Volume225.28K
52 Week high
$382.54
52 Week high$382.54
52 Week low
$183.03
52 Week low$183.03

Stock Snapshot

With a market cap of 9.37B, Krystal Biotech(KRYS) trades at $316.58. The stock has a price-to-earnings ratio of 41.44.

On 2026-10-17, Krystal Biotech(KRYS) stock moved within a range of $315.39 to $331.03. With shares now at $316.58, the stock is trading +0.4% above its intraday low and -4.4% below the session's peak.

Trading activity shows a volume of 225.28K, compared to an average daily volume of 275.29K.

Over the past 52 weeks, Krystal Biotech(KRYS) stock has traded between a high of $382.54 and a low of $183.03.

Over the past 52 weeks, Krystal Biotech(KRYS) stock has traded between a high of $382.54 and a low of $183.03.

KRYS News

Zacks 1d
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome

Krystal Biotech (KRYS Quick QuoteKRYS - Free Report) announced positive clinical data for KB113, its investigational intratumoral immunotherapy being deve...

KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Simply Wall St 2d
Krystal Biotech Posts Strong KB113 Data, Is The Stock Fully Priced? - Simply Wall Street

...

Krystal Biotech Posts Strong KB113 Data, Is The Stock Fully Priced? - Simply Wall Street
TipRanks 3d
Krystal Biotech provides clinical data for KB113 program

Krystal Biotech (KRYS) announced a clinical update supporting initial proof of concept for KB113, an intratumoral immunotherapy designed to drive sustained, loc...

Analyst ratings

92%

of 13 ratings
Buy
92.3%
Hold
7.7%
Sell
0%

People also own

Based on the portfolios of people who own KRYS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.